Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease

I. Fermo, S. V. D'Angelo, R. Paroni, G. Mazzola, G. Calori, A. D'Angelo

Research output: Contribution to journalArticle

235 Citations (Scopus)

Abstract

Objective: To evaluate the prevalence of moderate hyperhomocysteinemia and inherited thrombophilia disorders (congenital defects of the natural anticoagulant or fibrinolytic mechanisms) in patients with early-onset venous or arterial thromboembolic disease. Design: Cross-sectional 2-year evaluation of consecutive unrelated patients with a history of venous or arterial occlusive disease occurring before the age of 45 years or at unusual sites, in the absence of local predisposing factors. Setting: Thrombosis research unit of a community hospital. Patients: 107 patients with venous thromboembolism (mean age at event, 32.9 ± 11.9 years) and 50 patients with arterial occlusive disease (mean age at event, 31.1 ± 10 years) who did not have acquired coagulation defects, overt cancer, or acquired conditions affecting methionine metabolism. Measurements: Total plasma homocysteine (fasting levels), antithrombin III, protein C, protein S, activated protein C resistance, plasminogen, and heparin cofactor II were measured at least 3 months after the event. In 87 patients, total plasma homocysteine levels were also measured 8 hours after an oral methionine load was administered (L- methionine, 0.1 g/kg body weight). Ninety-fifth percentiles of the distribution of these variables were established in 60 apparently healthy persons; sex-specific ranges were used for protein S and total plasma homocysteine. Relatives of patients with laboratory abnormalities were studied to confirm inheritance of the defects. Results: Moderate hyperhomocysteinemia was detected in 13.1% (95% CI, 7.6% to 21.3%) and in 19.2% (CI, 9.0% to 31.9%) of patients with venous or arterial occlusive disease. The prevalence of hyperhomocysteinemia was almost twice as high when based on homocysteine measurements clone after oral methionine load as when based on fasting levels. The remaining defects were detected only in patients with venous occlusive disease (activated protein C resistance in 11.2% of patients, protein S or C deficiency in 6.6%, and plasminogen deficiency in 0.9%), with an overall prevalence of 18.7% (CI, 12.1% to 27.6%). Inheritance of hyperhomocysteinemia and of the other defects was confirmed in 26 of the 30 families studied. Event-free survival analysis showed that the relative risk for occlusive disease in patients with moderate hyperhomocysteinemia and other defects was 1.70 times (CI, 1.19 to 2.42; P <0.01) greater than in patients without defects. After adjustment for the presence of predisposing factors (for example, use of contraceptive drugs, pregnancy, surgery, prolonged bedrest, smoking, mild hypertension or dyslipidemia) and a family history of thrombosis, the age at first event of patients with moderate hyperhomocysteinemia was similar to that of patients with the other defects (26.4 ± 11.2 years compared with 25.2 ± 10.6 years), and the 43 patients with defects were significantly younger at first event than the 114 patients without defects (25.5 ± 11.1 years compared with 31.0 ± 12.3; P <0.005). Patients with mild hyperhomocysteinemia had a higher rate of recurrence than those without defects (52% compared with 25%; P = 0.01); among the 56 patients who had their first event more than 1 year before observation, the recurrence rate was higher (80% [CI, 51% to 95%]) in patients with defects than in patients without defects (41% [CI, 26% to 57%] P = 0.01). Conclusions: Moderate hyperhomocysteinemia may have pathogenic significance in premature venous and arterial occlusive disease and should be included among the (inherited) disorders of venous and arterial thrombophilia.

Original languageEnglish
Pages (from-to)747-753
Number of pages7
JournalAnnals of Internal Medicine
Volume123
Issue number10
Publication statusPublished - 1995

Fingerprint

Arterial Occlusive Diseases
Hyperhomocysteinemia
Homocysteine
Methionine
Activated Protein C Resistance
Thrombophilia
Plasminogen
Protein S
Causality
Fasting
Thrombosis
Heparin Cofactor II
Antithrombin Proteins
Prolonged Pregnancy
Protein S Deficiency
Protein C Deficiency
Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. / Fermo, I.; D'Angelo, S. V.; Paroni, R.; Mazzola, G.; Calori, G.; D'Angelo, A.

In: Annals of Internal Medicine, Vol. 123, No. 10, 1995, p. 747-753.

Research output: Contribution to journalArticle

@article{d5aa5f10d7554928a7b403f201c7a612,
title = "Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease",
abstract = "Objective: To evaluate the prevalence of moderate hyperhomocysteinemia and inherited thrombophilia disorders (congenital defects of the natural anticoagulant or fibrinolytic mechanisms) in patients with early-onset venous or arterial thromboembolic disease. Design: Cross-sectional 2-year evaluation of consecutive unrelated patients with a history of venous or arterial occlusive disease occurring before the age of 45 years or at unusual sites, in the absence of local predisposing factors. Setting: Thrombosis research unit of a community hospital. Patients: 107 patients with venous thromboembolism (mean age at event, 32.9 ± 11.9 years) and 50 patients with arterial occlusive disease (mean age at event, 31.1 ± 10 years) who did not have acquired coagulation defects, overt cancer, or acquired conditions affecting methionine metabolism. Measurements: Total plasma homocysteine (fasting levels), antithrombin III, protein C, protein S, activated protein C resistance, plasminogen, and heparin cofactor II were measured at least 3 months after the event. In 87 patients, total plasma homocysteine levels were also measured 8 hours after an oral methionine load was administered (L- methionine, 0.1 g/kg body weight). Ninety-fifth percentiles of the distribution of these variables were established in 60 apparently healthy persons; sex-specific ranges were used for protein S and total plasma homocysteine. Relatives of patients with laboratory abnormalities were studied to confirm inheritance of the defects. Results: Moderate hyperhomocysteinemia was detected in 13.1{\%} (95{\%} CI, 7.6{\%} to 21.3{\%}) and in 19.2{\%} (CI, 9.0{\%} to 31.9{\%}) of patients with venous or arterial occlusive disease. The prevalence of hyperhomocysteinemia was almost twice as high when based on homocysteine measurements clone after oral methionine load as when based on fasting levels. The remaining defects were detected only in patients with venous occlusive disease (activated protein C resistance in 11.2{\%} of patients, protein S or C deficiency in 6.6{\%}, and plasminogen deficiency in 0.9{\%}), with an overall prevalence of 18.7{\%} (CI, 12.1{\%} to 27.6{\%}). Inheritance of hyperhomocysteinemia and of the other defects was confirmed in 26 of the 30 families studied. Event-free survival analysis showed that the relative risk for occlusive disease in patients with moderate hyperhomocysteinemia and other defects was 1.70 times (CI, 1.19 to 2.42; P <0.01) greater than in patients without defects. After adjustment for the presence of predisposing factors (for example, use of contraceptive drugs, pregnancy, surgery, prolonged bedrest, smoking, mild hypertension or dyslipidemia) and a family history of thrombosis, the age at first event of patients with moderate hyperhomocysteinemia was similar to that of patients with the other defects (26.4 ± 11.2 years compared with 25.2 ± 10.6 years), and the 43 patients with defects were significantly younger at first event than the 114 patients without defects (25.5 ± 11.1 years compared with 31.0 ± 12.3; P <0.005). Patients with mild hyperhomocysteinemia had a higher rate of recurrence than those without defects (52{\%} compared with 25{\%}; P = 0.01); among the 56 patients who had their first event more than 1 year before observation, the recurrence rate was higher (80{\%} [CI, 51{\%} to 95{\%}]) in patients with defects than in patients without defects (41{\%} [CI, 26{\%} to 57{\%}] P = 0.01). Conclusions: Moderate hyperhomocysteinemia may have pathogenic significance in premature venous and arterial occlusive disease and should be included among the (inherited) disorders of venous and arterial thrombophilia.",
author = "I. Fermo and D'Angelo, {S. V.} and R. Paroni and G. Mazzola and G. Calori and A. D'Angelo",
year = "1995",
language = "English",
volume = "123",
pages = "747--753",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "10",

}

TY - JOUR

T1 - Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease

AU - Fermo, I.

AU - D'Angelo, S. V.

AU - Paroni, R.

AU - Mazzola, G.

AU - Calori, G.

AU - D'Angelo, A.

PY - 1995

Y1 - 1995

N2 - Objective: To evaluate the prevalence of moderate hyperhomocysteinemia and inherited thrombophilia disorders (congenital defects of the natural anticoagulant or fibrinolytic mechanisms) in patients with early-onset venous or arterial thromboembolic disease. Design: Cross-sectional 2-year evaluation of consecutive unrelated patients with a history of venous or arterial occlusive disease occurring before the age of 45 years or at unusual sites, in the absence of local predisposing factors. Setting: Thrombosis research unit of a community hospital. Patients: 107 patients with venous thromboembolism (mean age at event, 32.9 ± 11.9 years) and 50 patients with arterial occlusive disease (mean age at event, 31.1 ± 10 years) who did not have acquired coagulation defects, overt cancer, or acquired conditions affecting methionine metabolism. Measurements: Total plasma homocysteine (fasting levels), antithrombin III, protein C, protein S, activated protein C resistance, plasminogen, and heparin cofactor II were measured at least 3 months after the event. In 87 patients, total plasma homocysteine levels were also measured 8 hours after an oral methionine load was administered (L- methionine, 0.1 g/kg body weight). Ninety-fifth percentiles of the distribution of these variables were established in 60 apparently healthy persons; sex-specific ranges were used for protein S and total plasma homocysteine. Relatives of patients with laboratory abnormalities were studied to confirm inheritance of the defects. Results: Moderate hyperhomocysteinemia was detected in 13.1% (95% CI, 7.6% to 21.3%) and in 19.2% (CI, 9.0% to 31.9%) of patients with venous or arterial occlusive disease. The prevalence of hyperhomocysteinemia was almost twice as high when based on homocysteine measurements clone after oral methionine load as when based on fasting levels. The remaining defects were detected only in patients with venous occlusive disease (activated protein C resistance in 11.2% of patients, protein S or C deficiency in 6.6%, and plasminogen deficiency in 0.9%), with an overall prevalence of 18.7% (CI, 12.1% to 27.6%). Inheritance of hyperhomocysteinemia and of the other defects was confirmed in 26 of the 30 families studied. Event-free survival analysis showed that the relative risk for occlusive disease in patients with moderate hyperhomocysteinemia and other defects was 1.70 times (CI, 1.19 to 2.42; P <0.01) greater than in patients without defects. After adjustment for the presence of predisposing factors (for example, use of contraceptive drugs, pregnancy, surgery, prolonged bedrest, smoking, mild hypertension or dyslipidemia) and a family history of thrombosis, the age at first event of patients with moderate hyperhomocysteinemia was similar to that of patients with the other defects (26.4 ± 11.2 years compared with 25.2 ± 10.6 years), and the 43 patients with defects were significantly younger at first event than the 114 patients without defects (25.5 ± 11.1 years compared with 31.0 ± 12.3; P <0.005). Patients with mild hyperhomocysteinemia had a higher rate of recurrence than those without defects (52% compared with 25%; P = 0.01); among the 56 patients who had their first event more than 1 year before observation, the recurrence rate was higher (80% [CI, 51% to 95%]) in patients with defects than in patients without defects (41% [CI, 26% to 57%] P = 0.01). Conclusions: Moderate hyperhomocysteinemia may have pathogenic significance in premature venous and arterial occlusive disease and should be included among the (inherited) disorders of venous and arterial thrombophilia.

AB - Objective: To evaluate the prevalence of moderate hyperhomocysteinemia and inherited thrombophilia disorders (congenital defects of the natural anticoagulant or fibrinolytic mechanisms) in patients with early-onset venous or arterial thromboembolic disease. Design: Cross-sectional 2-year evaluation of consecutive unrelated patients with a history of venous or arterial occlusive disease occurring before the age of 45 years or at unusual sites, in the absence of local predisposing factors. Setting: Thrombosis research unit of a community hospital. Patients: 107 patients with venous thromboembolism (mean age at event, 32.9 ± 11.9 years) and 50 patients with arterial occlusive disease (mean age at event, 31.1 ± 10 years) who did not have acquired coagulation defects, overt cancer, or acquired conditions affecting methionine metabolism. Measurements: Total plasma homocysteine (fasting levels), antithrombin III, protein C, protein S, activated protein C resistance, plasminogen, and heparin cofactor II were measured at least 3 months after the event. In 87 patients, total plasma homocysteine levels were also measured 8 hours after an oral methionine load was administered (L- methionine, 0.1 g/kg body weight). Ninety-fifth percentiles of the distribution of these variables were established in 60 apparently healthy persons; sex-specific ranges were used for protein S and total plasma homocysteine. Relatives of patients with laboratory abnormalities were studied to confirm inheritance of the defects. Results: Moderate hyperhomocysteinemia was detected in 13.1% (95% CI, 7.6% to 21.3%) and in 19.2% (CI, 9.0% to 31.9%) of patients with venous or arterial occlusive disease. The prevalence of hyperhomocysteinemia was almost twice as high when based on homocysteine measurements clone after oral methionine load as when based on fasting levels. The remaining defects were detected only in patients with venous occlusive disease (activated protein C resistance in 11.2% of patients, protein S or C deficiency in 6.6%, and plasminogen deficiency in 0.9%), with an overall prevalence of 18.7% (CI, 12.1% to 27.6%). Inheritance of hyperhomocysteinemia and of the other defects was confirmed in 26 of the 30 families studied. Event-free survival analysis showed that the relative risk for occlusive disease in patients with moderate hyperhomocysteinemia and other defects was 1.70 times (CI, 1.19 to 2.42; P <0.01) greater than in patients without defects. After adjustment for the presence of predisposing factors (for example, use of contraceptive drugs, pregnancy, surgery, prolonged bedrest, smoking, mild hypertension or dyslipidemia) and a family history of thrombosis, the age at first event of patients with moderate hyperhomocysteinemia was similar to that of patients with the other defects (26.4 ± 11.2 years compared with 25.2 ± 10.6 years), and the 43 patients with defects were significantly younger at first event than the 114 patients without defects (25.5 ± 11.1 years compared with 31.0 ± 12.3; P <0.005). Patients with mild hyperhomocysteinemia had a higher rate of recurrence than those without defects (52% compared with 25%; P = 0.01); among the 56 patients who had their first event more than 1 year before observation, the recurrence rate was higher (80% [CI, 51% to 95%]) in patients with defects than in patients without defects (41% [CI, 26% to 57%] P = 0.01). Conclusions: Moderate hyperhomocysteinemia may have pathogenic significance in premature venous and arterial occlusive disease and should be included among the (inherited) disorders of venous and arterial thrombophilia.

UR - http://www.scopus.com/inward/record.url?scp=0028853921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028853921&partnerID=8YFLogxK

M3 - Article

VL - 123

SP - 747

EP - 753

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 10

ER -